Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

Kurhanewicz, John; Vigneron, Daniel B.; Ardenkjær-Larsen, Jan Henrik; Bankson, James A.; Brindle, Kevin; Cunningham, Charles H.; Gallagher, Firda A.; Keshari, Kayvan R.; Kjær, Andreas; Laustsen, Christoffer; Mankoff, David A.; Merritt, Matthew E.; Nelson, Sarah J.; Pauly, John M.; Lee, Philips; Ronen, Sabrina; Tyler, Damian J.; Rajan, Sunder S.; Spielman, Daniel M.; Wald, Lawrence; Zhang, Xiaoliang; Malloy, Craig R.; Rizi, Rahim

Published in:
Neoplasia

Link to article, DOI:
10.1016/j.neo.2018.09.006

Publication date:
2019

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Hyperpolarized $^{13}$C MRI: Path to Clinical Translation in Oncology

John Kurhanewicz*,1, Daniel B. Vigneron†,1, Jan Henrik Ardenkjaer-Larsen‡, James A. Bankson§, Kevin Brindle‖, Charles H. Cunningham‡‡, Ferdia A. Gallagher***, Kayvan R. Keshari††, Andreas Kjaer‡‡‡, Christoffer Laustsen§§§, David A. Mankoff†††, Matthew E. Merritt¶¶¶, Sarah J. Nelson†, John M. Pauly****, Philips Lee††††, Sabrina Ronen†, Damian J. Tyler§§§§, Sunder S. Rajan§§§§§, Daniel M. Spielman¶¶¶¶, Lawrence Wald###, Xiaoliang Zhang†, Craig R. Malloy*****,1 and Rahim Rizi††††,1

*Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA; †Department of Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, CA, USA; ‡Department of Electrical Engineering, Technical University of Denmark, Denmark; §Department of Imaging Physics, MD Anderson Medical Center, Houston, TX, USA; ¶Department of Biochemistry, University of Cambridge, Cambridge, UK; #Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; ††Department of Radiology, University of Cambridge, Cambridge, UK; ‡‡Department of Radiology, Memorial Sloan Kettering Cancer Center, NY, New York, USA; ‡‡‡Department of Clinical Physiotherapy, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Denmark; §§Department of Clinic Medicine, Aarhus University Hospital, Aarhus, Denmark; §§§Department of Radiology, University of Pennsylvania, PA, USA; ¶¶¶Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL, USA; ****Department of Electric Engineering, Stanford University, USA; ††††Functional Metabolism Group, Singapore Biomedical Consortium, Agency for Science, Technology and Research, Singapore; ‡‡‡‡Department of Biomedical Science, University of Oxford, Oxford, UK; §§§§Center for Devices and Radiological Health (CDRH), FDA, White Oak, MD, USA; §§ §§Departments of Radiology and Electric Engineering, Stanford University, USA; †††††Department of Radiology, Harvard Medical School, Boston, MA, USA; ††††‡Advanced Imaging Research Center, UT Southwestern Medical Center, Dallas, TX, USA

Abstract
This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) $^{13}$C magnetic resonance imaging’s (MRI’s)
widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized \(^{13}\text{C}\) MRI in 2011, preclinical studies involving \([1-^{13}\text{C}]\)pyruvate as well as a number of other \(^{13}\text{C}\) labeled metabolic substrates have demonstrated this technology’s capacity to provide unique metabolic information. A dose-ranging study of HP \([1-^{13}\text{C}]\)pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP \(^{13}\text{C}\) MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.

**Neoplasia** (2019) 21, 1–16

---

**Introduction**

Recent advances in cancer metabolism have generated considerable interest among clinicians.\(^1\)\(^2\) However, the only imaging agent regularly used in the clinic to assess metabolism is the glucose analog \([^{18}\text{F}]\) fluorodeoxyglucose (FDG), a positron emission tomography (PET) tracer that reports on local glucose uptake in many cancers, inflammation, and other processes. While FDG PET has been an extremely successful approach, it cannot assess downstream metabolism that is often important to more fully understand cancer. Hyperpolarized magnetic resonance imaging (HP MRI) provides a unique window into metabolic alterations based on its ability to measure molecular transformations of the imaging agent.\(^3\)\(^4\) The method dramatically, although temporarily, increases MRI signal, which allows in vivo imaging of biologically active molecules that was impossible with conventional methods. Dynamic nuclear polarization of \(^{13}\text{C}\)-labeled biomolecules (probes) is currently the dominant hyperpolarization process used for preclinical work, and it is the only one that has been translated to patient studies. Due to space limitations, this white paper will focus on dynamic nuclear polarization-based polarization of \(^{13}\text{C}\) probes, although there are other methods to generate HP \(^{13}\text{C}\)-probes including para-hydrogen and brute force–based approaches.\(^5\)\(^6\) and other nuclear magnetic resonance active nuclei such as \(^{129}\text{Xe}\), \(^{15}\text{N}\), and \(^{31}\text{P}\) have been hyperpolarized.\(^10\)\(^11\)

The potential to diagnose and better characterize cancer biology, predict cancer progression,\(^12\)\(^13\)\(^14\)\(^15\)\(^16\)\(^17\) and monitor early response to treatment\(^16\)\(^17\)\(^18\)–\(^33\) using HP MRI was highlighted in the first NIH white paper on this technology in 2011. Since then, a polarizer capable of producing hyperpolarized material for human injection was commercially introduced, and the safety of hyperpolarized \([1-^{13}\text{C}]\) pyruvate as a tool for measuring changes in tumor metabolism in patients was demonstrated.\(^34\) This white paper will highlight preclinical advances, technical needs, and early experience with patients and discuss how HP MRI might fill existing needs in current clinical research and practice. Finally, we will examine obstacles to HP MRI’s widespread clinical use and outline a path for clearing them.

---

**The Continuing Need for Animal Models**

In addition to providing the only plausible method for testing the feasibility and safety of new HP molecular probes, preclinical animal studies are crucial for refining the methods for their use in specific diseases and for validating quantitative HP measurements of metabolism against tissue assays. Animal studies also provide the opportunity to better understand fundamental aspects of biochemistry and its modification by disease, therapy, nutritional state, and prescribed experimental conditions, which is possible in preclinical models but not in patients. Even if some HP probes prove inappropriate for clinical translation, their use in preclinical studies can still yield information of real clinical value by elucidating the metabolic pathways that novel treatment strategies could target.\(^13\)\(^35\)\(^36\) Studies in animal models are also critical to drive basic science discovery of new metabolic drug interventions, where further applications of this technology might be beneficial in helping patients.

**HP Pyruvate for Diagnosis, Progression, and Response to Therapy**

\([1-^{13}\text{C}]\)pyruvate was among the first HP probes introduced and remains the most widely studied in preclinical cancer models because it is easy to polarize, \(T_1\) is relatively long, and it occupies a critical branch point central to a number of significant metabolic pathways. Pyruvate is the product of glycolysis, and its major fates include reduction to \([1-^{13}\text{C}]\)lactate via the enzyme lactate dehydrogenase (LDH) or oxidative metabolism to acetyl-coA with production of \([^{13}\text{C}]\) bicarbonate in the mitochondria. Both processes result in an altered chemical shift that HP MRI is able to image at uniquely high temporal resolution. Although some exceptions have been observed,\(^37\)\(^38\) the majority of preclinical cancer studies using HP pyruvate as a biomarker have shown increased conversion to HP lactate, consistent with the elevated lactate production (Warburg effect) that is an established characteristic of most cancerous cells.\(^12\)\(^17\)\(^39\)\(^40\)–\(^42\) These studies also demonstrated a mechanistic link between increased HP lactate signal and other cancer-associated cellular alterations such as the elevated expression of LDHA and monocarboxylate transporters, and lowered \(\text{pH}\) in the extracellular environment. The accompanying reduction in
pyruvate dehydrogenase activity can also be directly measured via appearance of HP [1-13C]bicarbonate from [1-13C]pyruvate or HP [5,13C]glutamate from [2,13C]pyruvate.19,20

Elevated transformation of hyperpolarized pyruvate to lactate has been established as a predictor of tumor progression in the transgenic adenocarcinoma of the mouse prostate "model" and genetically engineered pancreatic cancer models,43,44 while a similar effect was also seen in longitudinal studies of liver cancer models,45 alongside increased transamination of pyruvate to alanine. The latter effect appears to be specific to the hepatic tumor phenotype and may be diagnostic of tumor type or stage. These applications demonstrate HP MRI’s value as a tool for prognosis and treatment planning. In addition, the ability to measure the metabolic information at a key branch point involved in downstream glucose metabolism provides information that is unique and complementary to FDG PET. HP [1-13C]pyruvate MRI provides insight into metabolism of a substrate other than glucose, and the synergistic combination of the two methods may offer significant advantages in identifying and characterizing cancer. For example, it was recently demonstrated in a PET/MRI study where FDG-PET and HP MRI were simultaneously acquired (hyperPET) that FDG-PET cannot demonstrate the Warburg effect per se but does discriminate between glycolysis and oxidative phosphorylation in contrast to HP MRI.46,47

HP MRI of pyruvate and its products is sensitive to the effects of anticancer therapies including DNA-damaging agents, radiotherapy, antivascular agents, targeted therapies, hormonal therapy, and antimetabolites—all of which have been reported to lead to a drop in HP lactate labeling, mediated by different mechanisms in the various treatments.9,11–15 Additionally, the metabolism of HP fumarate to malate is sensitive to therapies that induce necrosis, such as VEGF neutralization and chemotherapy.31,33,48 Despite some exceptions,38,48 in general, preclinical data suggest that measurements from HP MRI of pyruvate predicts posttherapy cancer viability and aggressiveness. It will be important to preclinically test the hypothesis that therapeutic response can be determined at an earlier stage than that at which reduced tumor size is observable using anatomic imaging modalities as is done in the Response Evaluation Criteria in Solid Tumors approach.49 Given the needs of a personalized approach to treatment, HP MRI’s capacity to expedite assessment of response to therapy holds obvious value; this may be especially true in the case of early detection of nonresponse to therapy, which would enable more rapid adoption of alternate treatment strategies.

Existing and Prospective Probes

Numerous molecules in addition to [1-13C]pyruvate have been successfully polarized and used to study multiple biological processes, including [2-13C]pyruvate, [1-13C]acetate, [1-13C]alanine, 13C urea, [15N2]urea, perdeuterated [U-13C6]glucose, [1-13C]bicarbonate, [1,4-13C2]fumarate, and several others.50,51 [1-13C]acetate has been used to study tricarboxylic acid cycle flux and fatty acid oxidation in heart and skeletal muscles through its conversion to acetyl-CoA by acetyl-CoA synthase.32,52 While HP butyrate has been utilized to study ketone body metabolism and short-chain fatty acid pathways,54 HP alanine has been employed as an alternate probe to study metabolism in the muscle and liver.55,56 HP glucose has been used to monitor flux via the pentose phosphate pathway, as well as glycolytic flux and lactate production.57,58 HP [1-13C]dehydroascorbate has been imaged and used to monitor intercellular redox status and to inform on response to treatment by measuring the modulation of the tumor microenvironment.59–61 HP [1-13C]alpha-ketoglutarate has been used to track the neomorphic oncogenic activity of mutant IDH via its metabolism to the oncometabolite 2-hydroxyglutarate and glutamate.62,63 More recently, HP [1-13C]glutamine has been used to directly measure metabolic flux to 2-hydroxyglutarate, demonstrating a methodology to trace nutrient of origin to a product in vivo.64 HP [2-13C]dihydroxyacetone has been used to assess hepatic gluconeogenesis,65 while HP acetocacetate has been proposed as an indicator of mitochondrial redox status, although its utility has not yet been studied in tumors.66 The utility of inert metabolic probes such as 13C-Urea or 13C,15N2-urea has also been shown in simultaneous acquisitions with metabolized species as a means to normalize delivered agent concentration and uptake kinetics, or as independent markers of perfusion in tumor tissue.67 This combined acquisition has the potential to alleviate technical challenges in accurately determining metabolic and hemodynamic changes associated with treatment response.

Numerous biologically relevant, potentially polarizable molecules remain unstudied,18 and new HP probes to detect and assess response to various types of cancer treatment are urgently needed. For example, because MRI of HP pyruvate is unable to differentiate increased lactate production associated with tumor cells from that associated with inflammatory cells, other probes—such as the recently tested HP [6-13C]arginine—are necessary for monitoring response to therapies that target this cell type.72 In addition, the development of hyperpolarized biomarkers capable of monitoring response to the most promising immunotherapies currently in use, such as checkpoint inhibitors, is a major unmet need which should command immediate preclinical attention. Probes tailored to the innate or designed metabolic characteristics of such cellular therapeutic agents would be extremely valuable for assessing treatment efficacy at a very early stage.

Further Avenues of Preclinical Animal Study

Preclinical animal studies enable investigation of appropriate methods to report HP data or integrate multiple HP measurements, for example, through the development and testing of methods for the true simultaneous measurement of perfusion and metabolism to improve quantitation69 and facilitate identification of poorly perfused but metabolically active disease that is often highly aggressive and difficult to treat.73 The possibility of acquiring such a combined measurement was demonstrated using copolarized [1,13C]pyruvate and 13C Urea in rats: metabolic alterations were registered via the conversion of pyruvate into 13C bicarbonate, while alterations in perfusion were measured via changes in myocardial signals of pyruvate and urea.60 The development of HP probes and pulse sequences capable of simultaneously measuring perfusion/metabolism mismatch in cancerous tissue has the potential to provide valuable information regarding tumor heterogeneity, with obvious implications for the development of more sensitive and personal treatment.73 Similar possibilities exist for additional ratiometric measurements (e.g., local pH derived from CO2/HCO3 ratio,74–78 or redox state in different intracellular compartments derived from lactate/pyruvate ratio,79,80 α-ketoisocaproate:leucine ratio,81,82 or ascorbate:dehydroascorbate ratio).59,60 These combinations are being explored or developed in animal, organ, and cell research models with the potential for future clinical application. The unique ability to image multiple metabolites simultaneously—either through the injection of a single hyperpolarized agent that is variously metabolized or via the injection of several HP agents at once—means that HP MRI technology...
is particularly suited to this kind of combined measurement. Because ratiometric measurements are potentially subject to bias in the case of differing uptake or relaxation characteristics, preclinical models are critical for validation using histological and invasive techniques that are not practical in human subjects.

In addition to exploring HP technology, preclinical animal studies enable measurements that are not feasible in human subjects for reasons such as invasiveness, toxicity, or the current inability to hyperpolarize substrates in sufficient volume. Studies using genetically engineered and patient-derived xenograft models enable the combined use of PET and HP MRI, as well as the collection of a robust spectrum of supporting in vivo and histological measurements, including metabolite and enzyme profiles as well as histochemical measurements of enzyme heterogeneity, which can both confirm and enhance the data collected via these primary imaging modalities. While the ability to collect such supplementary measurements is undoubtedly crucial to validating the accuracy of primary measurements enabled by HP probes, its ultimate value may lie in the more general expansion of our understanding of the biochemical properties characteristic of specific disorders. For example, HP probes are currently being used to assess the progression of lung and brain injury, yielding valuable insights into the mechanism of injury propagation. While these studies are not directly applicable to imaging human injury using HP agents in the clinic, the information gained will help guide therapeutic approaches that could have significant clinical impact.

**Needs and Future Directions**

There is substantial need for preclinical polarizers capable of achieving high polarization and tailored for producing masses of material suitable for rodent exams. Such a polarizer that is less expensive than a clinical device would dramatically expand preclinical efforts and speed clinical investigations. High levels of polarization increase the signal-to-noise ratio and potentially open up previously undetectable biological pathways for study. High levels of polarization may also allow a reduction in the injected probe concentration. HP probes are injected at physiologic or supraphysiologic doses, and preclinical studies investigating the extent to which physiologic concentrations of HP probe might perturb in vivo metabolism relative to a tracer approach like PET are key to the proper interpretation of HP MRI findings. As previous work has demonstrated, this increased polarization is most easily achieved by employing higher magnetic fields and lower temperatures during the polarization process.

Optimized pulse sequences can also be used to preserve the magnetization of specific hyperpolarized substrates while enhancing the detection of products. Since the lack of standardized techniques remains an obstacle to the growth of HP MRI as a field of study, this represents a potential opportunity for the research community to collaborate with small imaging system manufacturers on the creation of standard imaging sequences and basic processing protocols, thereby possibly expanding the use of HP MRI techniques beyond labs with a strong MRI physics focus. Other beneficial technical improvements would include the development of a less complex user interface, as well as a more direct, rapid mechanism for the delivery of polarized agents into the animal or cell or tissue culture bioreactor.

The development and optimization of new hyperpolarized molecular probes, and preclinical studies that accurately recapitulate important aspects of human disorders—whether using primary cells and tissues, genetically engineered, patient-derived xenograft, or other models—continue to be of great value. Robust mechanistic validation linking hyperpolarized metabolic observations to established biological events are also essential to establish the value of hyperpolarized imaging approaches and their potential limitations. Significant effort is currently under way—and should be further encouraged—to explore the use of HP imaging biomarkers to inform on a variety of disease conditions and therapeutic strategies and to integrate this unique new information to positively affect outcome. The combined use of targeted therapeutic approaches and HP MRI in these models will provide a framework for accessing HP biomarkers of treatment response for clinical translation. It is also important to conduct more studies to validate the use of HP MRI in combination with other imaging modalities such as PET, as was recently done during a single imaging session in a canine cancer model. The value of combining these measurements lies not only in a more complete characterization of the cancerous tissue being imaged but in reduced scan time and more efficient use of resources.

**Necessary Technical and Analytic Developments**

Success with preclinical studies encouraged a more translational focus. In order to enable clinical trials, several specific technical developments were necessary. In the following section, we will outline some of the recent technical progress and note additional opportunities.

**A Device for Polarization**

Over the past 10 years, there have been significant improvements in polarizer hardware, from initial prototypes suitable for rodent exams to current commercial products that can support human studies. The performance in terms of polarization and speed of delivery has been adequate for initial [1-13C]pyruvate studies, but further developments are needed to achieve higher and faster polarizations reliably with increased cost-effectiveness, and to streamline methods of HP probe sterile delivery for pyruvate and other HP probes for future clinical research. Next-generation polarizers that are optimized for preclinical research will also be vital for supporting the development of new hyperpolarized agents and their use in basic science and translational research.

**Imaging Hardware**

Another important commercial goal should be improved 13C MR imaging hardware. While each major MR scanner vendor offers product hardware enabling the excitation and detection of hyperpolarized signals at the 13C frequency, several additional modifications would significantly improve the performance and applicability of this technology. Commercially available double-tuned body coils would greatly benefit human studies by allowing uniform excitation for 13C over any target disease site, as is the case for conventional 1H MRI. Current studies have been limited by both the 13C detector hardware and short acquisition times due to metabolism, signal relaxation, and excitation losses; thereby necessitating the use of strategies that more efficiently encode magnetization. As in 1H MRI, detector arrays with a high number of elements can facilitate higher acceleration rates to generate images faster and with increased spatial coverage and resolution. For optimal clinical studies, scanners with a greater number of receive channels (at least 32 channels) are needed to support 13C detector arrays with geometries that are optimized for all
body regions. Dual-tuned or nested receive arrays that would permit high-quality “standard of care” $^1$H MRI alongside sensitive $^{13}$C detection without repositioning or replacing coils in order to enhance patient comfort and workflow. Higher-performance gradients will also be critical for improving the speed, coverage, and performance of HP $^{13}$C MRI, which requires four times higher gradient strengths to achieve the same effect as for $^1$H MRI. The progress seen in highly parallel acquisition of $^1$H MRI over the past few years provides reason to believe that these radiofrequency (RF) coil challenges can be met within the constraints imposed by currently available gradient bores. The increased costs would be a very small fraction of total system cost and easily justified by the greatly enhanced capabilities. The development of appropriate phantoms that enable testing of new techniques for HP $^{13}$C MRI prior to human studies is also important for advancing the field. Static phantoms containing $^{13}$C-enriched compounds facilitate technical development and quality assurance testing to confirm scanner and coil performance at thermal equilibrium, while dynamic phantoms that simulate the kinetics of chemical conversion in vivo are important to develop and validate quantitative dynamic imaging measurements.

**Acquisition Methods for Human Studies**

The high signal-to-noise ratio provided by this hyperpolarization technique makes high-resolution acquisitions feasible. However, rapid metabolism and short $T_1$ relaxation times can limit the matrix size—and thus the spatial resolution and coverage possible—with conventional phase-encoding. The MR acquisition techniques used for initial animal studies and the first human trial were limited in spatial coverage (typically <8 cm) and dynamic temporal information. This clinical trial used single-slice dynamic $^{13}$C echo-planar spectroscopic imaging (EPSI) in some patients to estimate the correct starting time for a 12-second 3D EPSI single time-point acquisition in subsequent patients with a small FOV of 8-10 cm. Dynamic 1D EPSI measurements efficiently encode frequency and space along the readout direction following a single excitation. Extension to multiple spatial dimensions requires additional excitations and phase encoding repetitions for each dynamic time point. New acquisition and analysis techniques are needed for volumetric, dynamic HP MR data with improved spatial coverage and temporal resolution. Most preclinical and clinical research studies have used spectroscopic-based acquisitions, but imaging-based acquisitions including balanced steady-state free precession sequences, spectral-selective echo-planar, and spiral trajectories have clear advantages in terms of speed and ease of implementation and analysis. Methods combining $^{13}$C and $^1$H excitation and reception could benefit the detection of many metabolites via decoupling and indirect detection.

**Reconstruction, Dynamic Modeling, and Enzyme Rate Constants**

Ideal dynamic MRSI data would be resolved in three spatial dimensions, the spectral dimension, and time with adequate coverage and speed to enable reliable quantification of metabolic parameters. Fortunately, the spectrum is sparse, with only a few spectral lines. In addition, the time dimension is slowly varying. These two features allow the amount of encoding required to be greatly reduced by using compressed sensing reconstructions along with low-rank or model-based reconstruction in the temporal dimension. Spatial data reduction strategies, including parallel and constrained imaging methods, are crucial for reducing the number of excitations that are necessary to reconstruct dynamically changing data.
Excitation pulses preserve HP magnetization, allowing for increased coverage, higher excitation angles, or prolonged interaction with target biology. Optimized excitation schemes are required to permit further sensitivity enhancement.

Parallel imaging reconstructions can be challenging since signal at thermal equilibrium is too weak for practical measurement of sensitivity maps. Autocalibrating methods such as GRAPPA (GeneRalized Autocalibrating Partial Parallel Acquisition) can avoid wasting polarization and imaging time acquiring sensitivity maps but can be problematic because the fully sampled central region can be a large fraction of the sampled k-space volume which limits acceleration. Care must also be taken to ensure that undersampled parallel imaging data are acquired in such a way that the data are self-consistent enough to satisfy fundamental assumptions about the relationship between undersampled data. Alternatively, undersampled k-space data can be used to compute the coil sensitivities as with a calibration-less approach for HP $^{13}$C MR. Further investigations are needed to develop acquisition strategies that minimize uncertainty while maximizing the efficiency of spatial, temporal, and spectral encoding—including methods that exploit redundant information that could be derived from conventional $^1$H MRI.

MRI of hyperpolarized substrates is unique among diagnostic imaging modalities in its ability to provide information about dynamic chemical interactions and imaging agent metabolism. New approaches for characterizing the transient interaction between the imaging agent and targeted biological processes are therefore required. A variety of approaches have been proposed, including semiquantitative area under the curve measurements—such as the normalized lactate ratio—that reflect the ratio of locally observed product to precursor and product, “snapshot” measurements of metabolite...
distribution, or ratiometric values at a single time point. Pharmaco-
kinetic analysis of dynamic multispectral data has shown the ability in both preclinical and human studies (Figure 1) to derive rate constants for substrate conversions such as $k_{PL}$, the spectroscopic/imaging biomarker for the calculated rate at which HP pyruvate is converted into lactate. Quantitative measures such as $k_{PL}$ can provide important quantitative parameters for many applications where precise measurements are needed to quantify changes in specific drivers of aerobic glycolysis. Recent literature shows the strong correlation between perfusion and metabolic measures of $k_{PL}$ with cancer aggressiveness and response to therapy. To realize the inherent promise of the unprecedented new information afforded by HP substrates, further research is critically needed to develop and test new accurate, reproducible quantitative analysis methods.

Once achieved, the technical and analytical developments outlined above should help to significantly accelerate the translation of HP $^{13}$C MRI to the clinic and increase its biomedical value—both by enabling studies which offer further proof of the improved molecular imaging capabilities it has already displayed and by optimizing their potential clinical utility.

**Translation to Patients with Cancer**

The first-in-human study convincingly demonstrated that injection of HP [1-$^{13}$C]pyruvate is safe and that imaging metabolic products of hyperpolarized [1-$^{13}$C]pyruvate metabolism is feasible. Since then, a number of significant technical improvements relevant to improving data quality and preserving safety have been implemented. These include improved technology and strategies for generating sterile hyperpolarized material using a commercial device, the SPINlab, new MR data acquisition sequences, and multichannel $^1$H/$^{13}$C radio frequency RF coils. Pictured in Figure 2 is the workflow for the current-generation SPINlab which is now used routinely in patient studies and provides automated polarization, dissolution, and quality assurance system. The SPINlab polarizer uses a 5-T magnetic field and operates at ~0.8 K. It has the capacity to polarize up to four samples simultaneously, thus opening the door for the injection of multiple HP probes within a single imaging exam. A critical part of the SPINlab polarization and quality assurance process is the fluid path that enables polarization in a closed system to minimize the potential for microbial contamination. Compared to the initial human study using a prototype polarizer in a clean room, the achievable polarization of [1-$^{13}$C]pyruvate has more than doubled (from $\approx18\%$ to $\approx40\%$), and the time to delivery of HP $^{13}$C pyruvate was reduced (from $\approx68$ seconds to $\approx55$ seconds). Around the world, seven sites have performed human exams using the SPINlab polarizer, and more than 20 have been installed.

While initial patient studies have focused on [1-$^{13}$C]pyruvate, [2-$^{13}$C]pyruvate has recently been FDA approved and is being added
to $[1-\text{^{13}C}]$pyruvate in ongoing clinical trials. Additionally, funded clinical research studies are working toward the use of $^{13}$C urea, $[5-\text{^{13}C}]$glutamine, $[1-\text{^{13}C}]$alpha-ketoglutarate, and $[1,4-\text{^{13}C}_2]$fumarate in patient studies. To aid with submitting investigator-initiated Investigational New Drug (IND) applications for future patient studies, the IND for the use of $[1-\text{^{13}C}]$pyruvate was transferred to the NCI and is available on the following website (https://imaging.cancer.gov/programs_resources/cancer-tracer-synthesis-resources/hyperpolarized-C13-pyruvate-documentation.htm).

### Early Patient Validation Studies

Early patient validation studies involving test-retest reproducibility, correlations with pathologic findings, and clinical outcomes such as survival and disease progression after treatment have been initiated (data available from clinicaltrials.gov). In a study utilizing 2D dynamic EPSI of prostate cancer patients (NCT02421380), time to max pyruvate was reproducible when corrected for the arterial input function with no significant difference observed in repeat injections of the same patient within the same exam. 106 In two recent clinical trials of prostate cancer patients preprostatectomy (NCT02526360) and before and after treatment (NCT02911467), a 3D dynamic compressed sensing EPSI sequence was used to obtain full prostate coverage and to model the apparent rate of pyruvate to lactate conversion, $k_{PL}$. In the setting of advanced prostate cancer, early (6 weeks) after effective androgen deprivation therapy, there was a significant early reduction in $k_{PL}$ that reseed changes in mp-$^1$H MRI and predicted clinical response (Figure 3). 107 Comparison with current state-of-the-art imaging modalities such as $^1$H MRI is key to determining the added value of HP $^{13}$C MRI, and with current HP $^{13}$C MRI studies expanding to metastatic sites within the body, 108,109 the synergy of HP MRI with currently used PET probes will also need to be investigated.

There are currently a number of single-institution HP $^{13}$C MRI clinical trials in the setting of breast, cervical, liver, and brain cancer, and an initial multisite clinical trial for prostate cancer (Table 1). Following promising preclinical studies in brain tumors, multiple sclerosis, and traumatic brain injury, the feasibility of using HP $^{13}$C MRI for evaluating brain metabolism in patient studies was recently demonstrated. 110,111 These studies demonstrated that $[1-\text{^{13}C}]$pyruvate are transported across the blood brain barrier and that conversion to $[1-\text{^{13}C}]$lactate can be detected in regions of both tumor and normal brain. Interestingly, the rate of conversion in normal brain was substantially higher than had previously been observed in anesthetized preclinical models. For dynamic slab-localized and 2-D
echo planar spectroscopic imaging data with 4-8 ml spatial resolution, it was also possible to observe the conversion of HP pyruvate to bicarbonate, which may discriminate between tumor and normal brain. Additional studies are needed to optimize the pulse sequences, RF coils, and experimental design to observe all three resonances at a finer resolution and with volumetric coverage. Single-institution studies that have been funded by the NIH include protocols for obtaining data from the normal brain, in primary brain tumors prior to image-guided surgery, and for comparing that conversion to \([1-^{13}C]\)lactate/\([1-^{13}C]\)pyruvate in patients pre- and posttreatment with radiation and temozolomide.

There are also several clinical trials investigating noncancerous diseases, such as cardiomyopathy, hypertrophy and hypertension, and fatty liver disease (Table 1). Altered cardiac energetics is known to play an important role in the progression toward heart failure, and a recent study demonstrated the feasibility of assessing pyruvate metabolism in vivo in humans.97 The appearance of \(^{13}C\)-bicarbonate signal after administration of hyperpolarized \([1-^{13}C]\)pyruvate was readily detected in a cohort of healthy controls, suggesting that this technology may 1 day allow a direct measure of flux through the PDC in the in vivo human myocardium, providing a means for understanding therapeutic approaches that target metabolism.

While prior and ongoing HP \(^{13}C\) MRI patient studies have addressed many of the initial obstacles, there remain a number of challenges to the robust clinical translation of hyperpolarized \([1-^{13}C]\) pyruvate MRI and its full FDA approval, as well as the translation of other new hyperpolarized probes into the clinic. These challenges are discussed in the following section.

### Challenges in Translation to Clinical Research and Practice

Compared to current metabolic imaging methods based on positron tomography, HP \(^{13}C\) MRI technology offers superior information yield about fluxes in metabolic pathways without the constraints of ionizing radiation. Nevertheless, while other potential benefits such as safety and patient acceptability may be substantial, the central question for clinical translation is whether HP \(^{13}C\) MRI provides actionable clinical information that is inaccessible by other methods. In examining how this question can be answered in the affirmative, we can take some cues from the use of FDG PET/CT.112,113

#### The Clinical Role of Imaging in Cancer

The traditional clinical roles for imaging in cancer are detection, diagnosis, staging, and monitoring therapy.114 More specifically, imaging techniques are typically used in the clinic to detect the tumor through screening; to guide cancer diagnosis, including tissue sampling; and to determine the extent of cancer spread. More recently, molecular imaging in particular has been used as a cancer biomarker to help direct treatment.115,116 Already demonstrated in animal models115 and initial patient studies,107 this capacity to rapidly detect response to treatment is perhaps the most promising in terms of clinical translation. Because a response to therapy prior to any change in tumor volume could occur within days, or even hours, the ability to detect this change could redirect therapy to improve therapeutic efficacy and avoid unnecessary toxicity for ineffective treatments, potentially saving lives and alleviating suffering.

The complexity, expense, and requirement for administering an imaging agent will likely limit HP MRI’s role as a primary screening tool. However, coupled to blood or urine metabolic biomarkers indicative of cancer risk and specific cancer metabolic signatures, HP MRI could provide a very powerful, targeted detection tool in stratified populations. It could play a key role in diagnosis, for example, as metabolic features identified by HP MRI might provide a both sensitive and specific means of identifying cancer and clarifying the benign or malignant nature of findings seen on anatomic imaging—as is the case in the application of FDG PET to pulmonary nodules detected by CT.118 Since HP MRI is readily coupled to the anatomic information acquired from standard MRI, it may also be particularly helpful in directing tissue sampling by identifying the sites most suspicious for cancer or, in the case of large cancer or widespread lesions, indicating the lesions that appear most aggressive. Finally, HP MRI could play a role in stratifying tumors identified by other imaging modalities. Also, the application of HP MRI for systemic staging is unlikely in the short term as it would require a whole-body capability similar to that of PET/CT, the development of which would have to overcome several technical challenges. However, as discussed above, these technical challenges are beginning to be addressed in ongoing phase II clinical trials of metastatic cancer.

Our understanding of cancer metabolism is primarily based on cell and murine models whose relevance to human malignancies is unclear. Consequently, in addition to the traditional roles of imaging in cancer management, HP MRI could provide clinical value based on its capacity to identify specific therapeutic targets in vivo in humans, i.e., serve as companion diagnostics. Accordingly, the presence of accelerated lactate production could direct the use of LDH inhibitors, while altered mitochondrial metabolism might suggest therapeutic options to renormalize metabolic activity.

### How Could HP Information Change a Therapeutic Decision?

Since the publication of the first white paper,3 a number of reports have appeared on the evaluation of cancer biomarkers and cancer imaging methods.114,117,119-122 HP \(^{13}C\) MRI holds great promise as an imaging biomarker of cancer. An imaging biomarker has been defined as an anatomic, biochemical, or molecular parameter detectable with an imaging method that is useful for establishing the presence or severity of disease.123,124 As we have already mentioned, metabolic alteration is an important phenotypic feature of cancer that predicts disease behavior and can itself be a therapeutic target.121,125 A critical consideration in the translation of a new biomarker into the clinic is the impact of the test necessary for obtaining this biomarker on clinical practice and patient outcome.119 In other words, does the test lead to better, more effective, and/or more cost-effective patient treatment? As a cancer molecular imaging biomarker, HP \(^{13}C\) MRI has the potential to address the following five clinical needs115:

First, HP MRI could prove beneficial by detecting disease prior to its initial clinical manifestation—in high-risk patients, for example—or as a secondary diagnostic test, indicating the likelihood that abnormal findings from screening or staging studies represent a malignancy. It could also prove valuable by helping to stratify disease severity after a diagnosis. Second, HP MRI could identify specific sites for tissue biopsy for cancer diagnosis and characterization. A third important benefit would be the capacity to predict disease progression based on evidence of metabolic hyperactivity or the integrity of metabolic pathways that enable metastasis. Fourth, HP MRI may provide an early, pharmacodynamic measure of drug efficacy, which could in turn predict the likelihood of therapeutic futility, by measuring the impact of a given drug on regional cancer
metabolism. If validated, this would be a significant clinical contribution, as it would enable the avoidance of ineffective chemotherapy with the attendant morbidity and expense. Finally, HP MRI could prove useful in evaluating prognosis and indicating overall response—using the eradication of aberrant metabolism as a highly predictive indicator of disease resolution, akin to the use of FDG PET/CT in lymphoma. In this context, the role of HP would be to determine whether or not treatment has eliminated the cancer, as well as to help determine if there is a need for additional treatment by predicting the likelihood of disease relapse or progression. In summary, biomarker applications are likely to represent the most compelling use of HP $^{13}$C MRI in relation to cancer since its unique ability to characterize and quantify cancer metabolism provides a means for inferring the impact of targeted therapeutic interventions.\textsuperscript{122,127}

What Will a Clinician Look for in Studies of HP Validation?

Experience with cancer diagnostics\textsuperscript{119,120} suggests that the general term “validation” may refer to distinct criteria: validity with respect to analytical results, validity for the purpose of a clinical diagnosis, and validity for the purpose of modifying patient care, which could also be termed clinical utility. In order to support the use of HP $^{13}$C MRI in clinical trials and clinical practice, investigations relevant to all three classes of data will be needed.

Analytic validity will be an important question, as clinicians will need to understand what HP $^{13}$C MRI is measuring and see evidence that these measurements are accurate. One approach to establishing the analytic validity of HP MRI is to compare its results with those of other PET-based tracer experiments. Demonstrating the reproducibility of hyperpolarized imaging exams is another important step and will require establishing standardized and repeatable methods for HP MR image acquisition and interpretation. Clinical validity, on the other hand, refers to the capacity of a test to separate a given patient population into two groups, such as those with and without a disease. To establish their clinical validity, HP MRI results must be compared to an accepted clinical standard such as the tissue or laboratory-based assays with which oncologists are most comfortable. Another important aspect of demonstrating HP MRI’s clinical validity will be its comparison to FDG and other PET imaging methods, and for this reason, investment in facilities capable of performing both exams is critical.

It is important to acknowledge, however, that establishing the clinical validity of a given technology does not in and of itself demonstrate that this technology should be used in patient care decisions. Rather, that determination is ultimately based on clinical utility, which refers to the technology’s capacity to appropriately direct patient care. In assessing the clinical utility of HP $^{13}$C MRI, clinicians will look for validation against clinical outcomes, accuracy (sensitivity, specificity, receiver operating characteristic area) versus a reference standard in diagnostic applications, and predictive accuracy in assessing therapeutic response. It will therefore be important to know to what extent the data provided by HP MRI accurately reclassify a patient, after all conventional studies are complete, into the proper category—classified either as normal (with a normal HP exam) or as disease (with an abnormal HP exam). Additional criteria will include the risk or discomfort of the exam relative to the new information it provides and, of course, the cost. Utility will be a key component of later clinical trials, in which assessment of the impact on patient outcomes and the cost of medical care provide data for coverage decisions by payers, which is one of the most important determinants of whether or not a new test is actually used in the clinic.\textsuperscript{119}

Comparison to Positron Tomography

Lessons learned from other quantitative molecular methods such as PET can help guide the approach to quantitative image analysis using HP MRI. For example, studies have shown that more sophisticated quantitative methods such as compartmental kinetic analysis can improve the ability to measure therapeutic response and predict patient outcomes;\textsuperscript{128} however, this improvement must be balanced against the ability to implement more complex methods in the clinic.\textsuperscript{129} Experience suggests that necessary simplification is best achieved by collecting detailed data in early studies and then testing the impact of simplification against more rigorous analytic approaches.\textsuperscript{130}

Combining HP MRI and PET data in kinetic analysis may be especially powerful in characterizing cancer metabolism, as the two methods provide complementary information. Long half-life and relatively straightforward image quantification make PET a robust method for quantifying flux through certain specific biochemical pathways, such as the flux of glucose through hexokinases as a measure of glycolysis or of thymidine through TK as a measure of cellular proliferation. However, since isotopic emissions are not impacted by the chemical species to which the isotope is attached, PET provides no information about the nature of the molecule attached to the label. HP $^{13}$C MRI, on the other hand, provides exquisite information on the evaluation of metabolites of the injected substance—such as from pyruvate—while its shorter half-life makes studies of metabolic trapping difficult. Taken together, the two methods can provide comprehensive information on metabolic fluxes, especially at major branch points in metabolic pathways such as the conversion of pyruvate to lactate in glycolysis.

Future Directions: Initial Studies and Clinical Study Design

Early Clinical Trials. Existing guidelines for designing and reporting on clinical trials of biomarkers provide a helpful template for HP $^{13}$C MRI.\textsuperscript{131} Early studies must refine and test robust methods for image acquisition and analysis to provide a uniform (and uniformly accepted) approach to be used in subsequent clinical trials. Early studies should also include tests of repeatability/precision to measure the qualitative and quantitative variability of HP imaging results, typically using a test/retest paradigm.\textsuperscript{113} Guidelines based on results from early clinical trials are important for subsequent trials and eventual clinical use, as the NCI consensus guidelines on FDG PET/CT have demonstrated.\textsuperscript{132} Finally, early clinical trials should validate HP $^{13}$C MRI against an accepted reference standard for cancer diagnosis and characterization, typically based on tissue sampling. This reference standard can be the presence or absence of cancer for diagnostic applications, or specific assays that might serve as a reference for imaging measures and which are often established in preclinical studies. In addition to standardizing imaging approaches, reporting of adverse events also could be standardized to facilitate regulatory approval down the road.

The latter phase of imaging trials for biomarker applications should evaluate new imaging tests for their accuracy in predicting important clinical cancer outcomes such as therapeutic response, progression-free survival, and overall survival. Early studies must establish the
value in clinical trials of HP $^{13}$C MRI as integrated markers, where novel imaging is embedded in a clinical trial but is collected in a purely observational fashion for comparison against clinical outcomes measured in the treatment trial. Once validated in integral biomarker trials, the imaging marker can be used to direct therapy in a clinical trial and, later, in clinical practice. An example can again be found in the application of FDG PET/CT to lymphoma, where the resolution of abnormal FDG uptake, known as a complete metabolic response, was shown to be highly predictive of disease-free survival and is now used as an integral marker in clinical trials and for clinical practice.

**Multisite Trials.** Multisite clinical trials will be expected prior to FDA approval of [1-$^{13}$C]pyruvate as an imaging agent, and certain specific obstacles will have to be addressed in designing them. In addition to requiring novel imaging hardware, acquisition methods, and analysis, HP $^{13}$C MRI carries the added challenge of requiring the administration of a short-lived, locally produced imaging probe, the production of which requires onsite personnel with expertise in producing HP agents, monitoring their quality, and assuring patient safety and regulatory compliance. The ability to produce uniformly high-quality HP imaging agents across multiple centers is therefore a crucial step in moving to multicenter clinical trials and eventual clinical practice. Once again, some lessons can be learned from recent multisite tests of investigational PET probes, which share many of these requirements. The foremost requirement is that of validated, uniform standards for probe production that will support equivalent probe quality across all sites involved participating in multicenter trials. This allows operation under a common regulatory framework—for example, an NCI-held IND for multicenter clinical trials—and assures patient safety and consistency of the drug product. Standardized, robust image acquisition methods are also needed, as are methods for testing and qualifying equipment and personnel involved in HP MRI studies to ensure high-quality imaging data at all participating sites.

Experience suggests a multistep approach leading to multicenter trials for novel imaging approaches such as MRI of HP [1-$^{13}$C] pyruvate will be key for obtaining full FDA approval. Early studies to test the potential accuracy and utility of new imaging methods are often best done in single-center studies at expert institutions invested in the technology. Early multicenter phase II trials should be small enough to assure the ability of sites to acquire the imaging data in a uniform and reproducible fashion and should validate the findings from single-center trials; indications supported by small multicenter trials can then be carried into larger phase III studies using well-defined, prospective procedures for image analysis, with study design and sample size calculations guided by results from smaller multisite or single-site trials. Larger phase II trials should include endpoints for safety and efficacy—in this case defined as diagnostic accuracy. These larger studies should also gather information on therapeutic impact and cost-effectiveness, key data for coverage decisions by the Center for Medicare and Medicaid Services and other payers.

**Recommendations for Future Research**

Since the publication of the first NIH white paper on hyperpolarized $^{13}$C MRI in 2011, numerous preclinical studies have demonstrated this technology’s unique metabolic imaging capabilities in the context of cancer. There have now been over 200 HP $^{13}$C MRI human studies performed to date worldwide at 7 different medical centers, and over 5 more sites plan to initiate patient studies within the next 6 months. All of these studies have shown that HP $^{13}$C pyruvate MRI is safe and also effective in detecting key metabolic conversions in patients with a variety of diseases and even in normal volunteers. It is important to recognize that demonstrating the clinical safety and feasibility of HP MRI technology is not enough to ensure its widespread clinical implementation. If the latter is to be achieved, it will be because future trials are able to successfully establish its *clinical utility*. In addition, widespread clinical implementation also implies regulatory approval and reimbursement approvals around the world. Commercialization of HP [1-$^{13}$C]pyruvate MRI will require a comprehensive regulatory and sponsorship strategy that will also depend on the potential clinical utility. We have developed a number of recommendations with this ultimate goal in mind.

First, it is necessary to continue refining the protocols, new HP agents, and investigative targets of ongoing preclinical studies in a translational direction with refined pharmacy methods for reliable, lower-cost production of sterile HP solutions. Also, it is valuable to verify that metabolic measurements in animal models of cancer and other disease states correspond to those performed in human disease, and to incorporate these measurements into disease hypothesis testing and development of new hyperpolarized agents. Improved quantitative analysis of metabolite signals and enzymatic rate kinetics obtained from HP [1-$^{13}$C] pyruvate will be a critical aspect of this. It is also imperative to identify the metabolic network(s) associated with the metabolism of specific hyperpolarized agents in order to select the appropriate agent for the study of specific disease conditions and therapies, and to appropriately guard against incorrectly associating apparent metabolic changes with the wrong cause. Additionally, there is a need for more studies which focus on determining the origins of variability in therapeutic response through separate HP measures of uptake and metabolism, and to use these HP probes to identify and better understand therapeutic response and nonresponders at earlier time points.

Further efforts to develop improved imaging pulse sequences and RF coils for imaging different organs, agents, and disease states will be critical for increased quality, information content, and applicability. New RF hardware should enable body-coil transmit and multichannel (32 at least) reception for all parts of the body with both $^{13}$C and $^1$H frequency excitation and reception. Analysis methods for the reliable calculation of enzymatic rate constants, such as $k_{PL}$ for the LDH catalyzed conversion of pyruvate to lactate and $k_{PYR}$ for pyruvate to bicarbonate, need to be refined and tested in patient and volunteer studies at multiple sites. In the context of cancer more specifically, another vital avenue for future studies will be the development of new HP agents capable of probing the ancillary and often-unexpected
metabolic changes leading to increased cancer cell survival after therapy. Specialized MR pulse sequences for the new agents will be required and $^1$H detected-$^{13}$C spectroscopy techniques should be developed and investigated for increased sensitivity with the added advantage that spatial information can be encoded at the $^1$H frequency.

There are also a number of needs to be addressed at an institutional level. First and foremost, the mechanism(s) for multisite clinical trials must be established—both through the identification of sites that possess the necessary equipment and by developing the appropriate investigative protocols. In order to support these efforts, it is important to promote the development of pedagogical resources for real-time metabolic imaging, perhaps through the establishment of new pre- and postdoctoral training programs focused on developing relevant techniques.

Finally, widespread clinical translation will not be possible without the continued development of robust collaborations among basic science investigators, clinical oncologists, and those with expertise in clinical study design. This collaborative work must be bolstered by strong partnerships between academia, funding agencies, and industry.

Acknowledgements
This report was initiated through discussions with representatives of the NCI Cancer Imaging Program and other NIH extramural programs (National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Biomedical Imaging and Bioengineering; and NIH Research Infrastructure Programs). The initial draft was reviewed and edited by over 60 scientists, followed by extensive discussions at a workshop at the ISMRM meeting in May 2017 with more than 52 scientists from academia, industry, and federal agencies from the United States and other countries. The authors appreciate the assistance from NIH extramural program staff Drs. Huiming Zhang, Maren Laughlin, Guoying Liu, Larry Clarke, Paula Jacobs, Janet Eary, and Lalitha Shankar during the development of this report and for organizing the workshop. The authors would also like to thank other contributors, namely, Drs. Michael Boss and Karl Stupic from NIST, Dr. Murali C. Krishna from NCI intramural, and Dr. Matthew G. Vander Heiden from MIT.

References
Neoplasia Vol. 21, No. 1, 2019 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. 13


